Ibrutinib bodes well for relapsed mantle-cell lymphoma

Progression-free survival was significantly better when patients with relapsed or refractory mantle-cell lymphoma were treated with oral ibrutinib than with intravenous temsirolimus, based on results from 280 patients in an international, randomized, open-label phase III trial. Study subjects had...
Source: Skin and Allergy News - Category: Dermatology Source Type: news